Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Circulating tumor DNA-based copy-number profiles enable monitoring treatment effects during therapy in high-grade serous carcinoma.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 1 Dec 2023

Nguyen Mai T N, Rajavuori Anna, Huhtinen Kaisa, Hietanen Sakari, Hynninen Johanna, Oikkonen Jaana, Hautaniemi Sampsa

Abstract excerpt

Circulating tumor DNA (ctDNA) analysis has emerged as a promising tool for detecting and profiling longitudinal genomics changes in cancer. While copy-number alterations (CNAs) play a major role in cancers, treatment effect monitoring using copy-number profiles has received limited attention as compared to mutations. A major reason for this is the insensitivity of CNA analysis for the real-life tumor-fraction...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to DNA Copy Number Variations

Share to Mutation

Share to Recurrence

Source

Identifiers

PMID: 37806091
DOI: 10.1016/j.biopha.2023.115630

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating tumor DNA-based copy-number profiles enable monitoring treatment effects during therapy in high-grade serous carcinoma.PMID 37806091Read ↗

Circulating Tumor DNA-Based Copy-Number Profiles Enable Monitoring Treatment Effects During Therapy in High-Grade Serous CarcinomaSemantic proximity Read ↗

Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian CancerSemantic proximity Read ↗

Copy number signatures and mutational processes in ovarian carcinoma.Semantic proximity Read ↗

Genome Wide DNA Copy Number Analysis of Serous Type Ovarian Carcinomas Identifies Genetic Markers Predictive of Clinical OutcomeSemantic proximity Read ↗

Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients.Semantic proximity Read ↗

Current Applications and Challenges of Next-Generation Sequencing in Plasma Circulating Tumour DNA of Ovarian CancerSemantic proximity Read ↗

Multi-Omics Characterization of ctDNA Release Mechanisms in Ovarian CancerSemantic proximity Read ↗

Selecting short DNA fragments in plasma improves detection of circulating tumour DNASemantic proximity Read ↗

The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma.Semantic proximity Read ↗

Noninvasive early differential diagnosis and progression monitoring of ovarian cancer using the copy number alterations of plasma cell-free DNASemantic proximity Read ↗

Copy number signatures in cervical samples enable early detection of high-grade serous ovarian carcinomaSemantic proximity Read ↗

Single-Cell NGS-Based Analysis of Copy Number Alterations Reveals New Insights in Circulating Tumor Cells Persistence in Early-Stage Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.